Vivimed Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivimed Labs has submitted an annual declaration to the stock exchanges under Regulation 31(4) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, for the financial year ended March 31, 2025. Promoter Santosh Varalwar, writing on behalf of all promoters, has confirmed that no encumbrance (such as pledge, lien, or hypothecation) was created directly or indirectly on the shares held by them in the company during the year. This is a yearly compliance requirement applicable to all promoter groups of listed companies, regardless of whether any encumbrance exists. The filing has been signed and submitted to both BSE and NSE on April 3, 2025.
This is a routine annual compliance disclosure with no material impact on the stock price. The confirmation that promoters have not pledged or encumbered their shares is mildly reassuring for retail investors, as it rules out near-term risks of forced share sales due to margin calls or loan defaults.